Europe Orders 750,000 Mpox Vaccines for 2026

According to the World Health Organization, mpox outbreaks remain a global health risk. Since mpox is a vaccine-preventable disease, access to the approved vaccine is essential.

To address this need, Bavarian Nordic A/S, a global vaccine company, recently issued the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement.

The initial order for 750,000 doses of the MVA-BN (JYNNEOS) smallpox/mpox vaccine announced on October 31, 2025, will be delivered in 2026 and is the result of a new joint procurement contract by the European Commission through HERA.

This represents the second order received in 2025, following the earlier award of a contract option from the U. S. Biomedical Advanced Research and Development Authority in the U.S. Department of Health and Human Services, announced in May.

Bavarian Nordic anticipates additional orders for MVA-BN over the course of the following year.

As of November 3, 2025, in the United States, the JYNNEOS vaccine is commercailly available at various health clinics and pharmacies.